Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.

J Antimicrob Chemother · 2023 · PMC10775154 · PMID 37671831

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Active drug use among patients with HIV/HCV coinfection was the only factor that showed a trend to an association with reduced SVR rates.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.